Sugi Predict

Sugi Predict / Compounds / SCHEMBL22802480

SCHEMBL22802480

SCHEMBL22802480

COc1cc(CBr)cc(F)c1C#N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CACNA1H O95180 1/20 0.39
▸ TRPV4 Q9HBA0 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ GRM2 Q14416 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ KCNJ1 P48048 1/20 0.34
▸ HTR2A P28223 3/20 0.33
▸ HTR2C P28335 3/20 0.33
▸ HTR2B P41595 3/20 0.33
▸ SQOR Q9Y6N5 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ NR3C1 P04150 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24340396 0.87 NPC1 (0.41) ALDH1A1CYP1A2CYP3A4CYP2C19HSD17B10
SCHEMBL12763938 0.86 PTGS2 (0.48) CACNA1HTRPV4ALDH1A1CYP1A2CYP3A4
SCHEMBL21596827 0.85 CACNA1H (0.41) CACNA1HTRPV4ALDH1A1CYP1A2CYP3A4
SCHEMBL21596854 0.85 NPC1 (0.39) CACNA1HTRPV4ALDH1A1CYP1A2CYP3A4
SCHEMBL29472383 0.84 ALDH1A1 (0.41) ALDH1A1CYP1A2CYP3A4CYP2C19HSD17B10
SCHEMBL17316422 0.83 TRPV4 (0.52) TRPV4
SCHEMBL15955655 0.82 CACNA1H (0.39) CACNA1HTRPV4ALDH1A1CYP1A2CYP3A4
SCHEMBL15955546 0.82 TNKS2 (0.41) CACNA1HTRPV4ALDH1A1CYP1A2CYP3A4
SCHEMBL31432491 0.82 CACNA1H (0.39) CACNA1HTRPV4ALDH1A1CYP1A2CYP3A4
SCHEMBL31535947 0.82 TRPV4 (0.34) TRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062406-A1 Benzisoxazole Sulfonamide Derivatives PFIZER (US) 2026-03-05 — — US disclosed
US-12545669-B2 Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives PFIZER INC. (US) 2026-02-10 — — US disclosed
EP-4667055-A2 KAT6 INHIBITOR METHODS AND COMBINATIONS FOR CANCER TREATMENT Pfizer Inc. (US) 2025-12-24 — — EP disclosed
EP-4181920-B1 KAT6 INHIBITOR AND COMBINATIONS FOR BREAST CANCER TREATMENT PFIZER (US) 2025-09-10 — — EP disclosed
EP-4299135-B1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2025-08-06 — — EP disclosed
US-12371425-B2 Benzisoxazole sulfonamide derivatives PFIZER INC. (US) 2025-07-29 — — US disclosed
US-20250122182-A1 MYST Inhibitors Isosterix, Inc. 2025-04-17 — — US disclosed
EP-3986890-B9 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2025-04-16 — — EP disclosed
US-20250051343-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES Isosterix, Inc. 2025-02-13 — — US disclosed
EP-4499609-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES Isosterix, Inc. (US) 2025-02-05 — — EP disclosed
US-20220251075-A1 Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives PFIZER INC. 2022-08-11 — — US disclosed
EP-3986890-A1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES Pfizer Inc. (US) 2022-04-27 — — EP disclosed
CN-114364672-A Benzisoxazole sulfonamide derivatives 辉瑞大药厂 2022-04-15 — — CN disclosed
WO-2022013369-A1 KAT6 INHIBITOR METHODS AND COMBINATIONS FOR CANCER TREATMENT PFIZER INC. (US) 2022-01-20 — — WO disclosed
WO-2022013369-A1 KAT6 INHIBITOR METHODS AND COMBINATIONS FOR CANCER TREATMENT PFIZER INC. (US) 2022-01-20 — — WO disclosed
WO-2020254946-A1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER INC. (US) 2020-12-24 — — WO disclosed
WO-2020254946-A1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER INC. (US) 2020-12-24 — — WO disclosed
US-20200399258-A1 Benzisoxazole Sulfonamide Derivatives PFIZER INC. 2020-12-24 — — US disclosed
WO-2020254989-A1 CYCLOALKYL AND HETEROCYCLOALKYL BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER INC. (US) 2020-12-24 — — WO disclosed
WO-2020254989-A1 CYCLOALKYL AND HETEROCYCLOALKYL BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER INC. (US) 2020-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051343-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES KAT6A, KAT6B, KAT2A CACNA1H 4201/4885TRPV4 4818/4885ALDH1A1 1618/4885
US-12371425-B2 Benzisoxazole sulfonamide derivatives BRIX1, RB1, BCR CACNA1H 4048/4885TRPV4 2910/4885ALDH1A1 550/4885
US-20200399258-A1 Benzisoxazole Sulfonamide Derivatives BRIX1, RB1, BCR CACNA1H 3948/4885TRPV4 2837/4885ALDH1A1 440/4885
US-20220251075-A1 Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives BRIX1, CCNA1, RB1 CACNA1H 4647/4885TRPV4 3796/4885ALDH1A1 1117/4885
US-12545669-B2 Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives NHERF1, CBX8, BCL9 CACNA1H 1413/4885TRPV4 3366/4885ALDH1A1 1527/4885
US-20250122182-A1 MYST Inhibitors MNAT1, SUGT1, ACAT2 CACNA1H 4642/4885TRPV4 4752/4885ALDH1A1 3906/4885
US-20260062406-A1 Benzisoxazole Sulfonamide Derivatives KAT8, KAT5, KAT7 CACNA1H 951/4885TRPV4 3638/4885ALDH1A1 1927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.